Retention of transforming growth factor β1 using functionalized dextran-based hydrogels

被引:32
作者
Maire, M
Logeart-Avramoglou, D
Degat, MC
Chaubet, F [1 ]
机构
[1] Univ Paris 13, Bichat Hosp, ERIT M 0204, INSERM,Lab Bioingn Polymeres Cardovasc, F-75877 Paris 18, France
[2] Univ Paris 07, Lab Rech Orthoped, CNRS, UMR 7052,Fac Med Lariboisiere St Louis, F-75877 Paris 18, France
关键词
hydrogel; functionalized dextran; TGF-beta; 1; drug delivery; sodium trimetaphosphate;
D O I
10.1016/j.biomaterials.2004.06.003
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Functionalized dextrans (FD) are anionic water-soluble polymers bearing carboxylate, benzylamide and sulfate groups, which exhibit binding capacity to transforming growth factor-beta1 (TGF-beta1). In this paper, we have investigated the ability of dextran-based hydrogels containing FD, to bind and release recombinant human TGF-beta1. Hydrogels were prepared by chemical crosslink native dextran and FD with sodium trimetaphosphate in I m NaOH at 50degreesC. A wide range of hydrogels were prepared as particles ranging of 1-1.6 mm of diameter and characterized with various amounts of FD and with different crosslinker feeding ratios (CFR). Dried particles were soaked with recombinant human transforming growth factor-beta1 (rhTGF-beta1) to determine their capacity to deliver the growth factor. Results indicated that the in vitro kinetics releases of rhTGF-beta1 were related to FD and CFR. Retention capacity of rhTGF-beta1 increases with an increase of negative charges of the matrices brought by both phosphate linkages, and FD as demonstrated by an additional release of growth factor in high ionic strength solution. Highly crosslinked hydrogels that contained the highest amount of FD (18% (w/w)) retained up to 88% of rhTGF-beta1. Bioactivity of released growth factor was confirmed in a cell assay. These functionalized hydrogels may have important uses for the stabilization and the protection of rhTGF-beta1 as entrapment systems and could be applied to other proteins of clinical interest. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1771 / 1780
页数:10
相关论文
共 41 条
[1]   AN ASSAY FOR TRANSFORMING GROWTH-FACTOR-BETA USING CELLS TRANSFECTED WITH A PLASMINOGEN-ACTIVATOR INHIBITOR-1 PROMOTER LUCIFERASE CONSTRUCT [J].
ABE, M ;
HARPEL, JG ;
METZ, CN ;
NUNES, I ;
LOSKUTOFF, DJ ;
RIFKIN, DB .
ANALYTICAL BIOCHEMISTRY, 1994, 216 (02) :276-284
[2]   Biodegradable amphiphilic multiblock copolymers and their implications for biomedical applications [J].
Bae, YH ;
Huh, KM ;
Kim, Y ;
Park, KH .
JOURNAL OF CONTROLLED RELEASE, 2000, 64 (1-3) :3-13
[3]   Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7) with the FGF2 autocrine loop [J].
BagheriYarmand, R ;
Liu, JF ;
Ledoux, D ;
Morere, JF ;
Crepin, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 239 (02) :424-428
[4]   Materials for protein delivery in tissue engineering [J].
Baldwin, SP ;
Saltzman, WM .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (1-2) :71-86
[5]   Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release [J].
Chinen, N ;
Tanihara, M ;
Nakagawa, M ;
Shinozaki, K ;
Yamamoto, E ;
Mizushima, Y ;
Suzuki, Y .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2003, 67A (01) :61-68
[6]  
de Raucourt E, 1998, J BIOMED MATER RES, V41, P49, DOI 10.1002/(SICI)1097-4636(199807)41:1<49::AID-JBM6>3.0.CO
[7]  
2-Q
[8]   Cross-linked amylose as matrix for drug controlled release. X-ray and FT-IR structural analysis [J].
Dumoulin, Y ;
Alex, S ;
Szabo, P ;
Cartilier, L ;
Mateescu, MA .
CARBOHYDRATE POLYMERS, 1998, 37 (04) :361-370
[9]   Phosphated crosslinked guar for colon-specific drug delivery I. Preparation and physicochemical characterization [J].
Gliko-Kabir, I ;
Yagen, B ;
Penhasi, A ;
Rubinstein, A .
JOURNAL OF CONTROLLED RELEASE, 2000, 63 (1-2) :121-127
[10]  
HAMILTON RM, 1965, STARCH CHEM TECHNOLO, P351